Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

Acambis -Bavarian Nordic

15 Posts
| Omlaag ↓
  1. [verwijderd] 26 augustus 2005 07:40

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Acambis turns to America in defence of patent claim

    By Stephen Foley
    Published: 25 August 2005

    Acambis, the Cambridge-based vaccines company which developed a jab against smallpox, is set to rely on its relationship with the US government as it prepares to defend allegations of stealing trade secrets and breaching a rival's patents.

    The company was served with a claim for damages last week by its Danish rival, Bavarian Nordic, which claims Acambis used secrets revealed to it in licensing negotiations in 2002.

    The two are in an increasingly bitter race to develop a second-generation smallpox vaccine that the US government can use to inoculate people whose immune systems are too weak to take traditional vaccines. The victor could win a contract worth $1bn (£555m). And Acambis's lawyers are drawing up a robust defence that claims the US government itself gave the company the detailed scientific knowledge it has used. That science is not patent-protected, Acambis will argue.

    Details of Bavarian Nordic's specific allegations have emerged in court papers from the US. These say Acambis's chief scientific officer, Thomas Monath, and a team from the company were shown details of clinical data, dosing and production conditions for the weakened smallpox vaccine - MVA - at a meeting at Acambis's offices on 12 June 2002. The companies signed a "secrecy agreement" before the meeting, it is alleged. Acambis requested a licensing proposal, but backtracked, it is claimed.

    The two sides were negotiating a deal whereby Acambis would license intellectual property surrounding MVA. But Acambis signed a deal with the US government's National Institutes of Health (NIH), which had been working on MVA. Bavarian says the NIH was using its secrets, which were not the US government's to sign away.

    It tried unsuccessfully to prevent the NIH from releasing its MVA strain to Acambis, the court documents reveal. "The virus was originally provided to Dr Moss [Bernard Moss of the NIH] for research and not for commercialisation into vaccine products," it claims.

    The NIH was keen to generate a competitive tender for the contract to supply up to 80 million doses of MVA, which could be worth $1bn. It faced domestic criticism for awarding a contract for a stockpile of anthrax drugs to a single supplier, and it is expected that the MVA contract will be shared between Acambis and Bavarian Nordic.

    Acambis refused to comment yesterday on the specifics revealed in the court documents.

    Acambis, the Cambridge-based vaccines company which developed a jab against smallpox, is set to rely on its relationship with the US government as it prepares to defend allegations of stealing trade secrets and breaching a rival's patents.

    The company was served with a claim for damages last week by its Danish rival, Bavarian Nordic, which claims Acambis used secrets revealed to it in licensing negotiations in 2002.

    The two are in an increasingly bitter race to develop a second-generation smallpox vaccine that the US government can use to inoculate people whose immune systems are too weak to take traditional vaccines. The victor could win a contract worth $1bn (£555m). And Acambis's lawyers are drawing up a robust defence that claims the US government itself gave the company the detailed scientific knowledge it has used. That science is not patent-protected, Acambis will argue.

    Details of Bavarian Nordic's specific allegations have emerged in court papers from the US. These say Acambis's chief scientific officer, Thomas Monath, and a team from the company were shown details of clinical data, dosing and production conditions for the weakened smallpox vaccine - MVA - at a meeting at Acambis's offices on 12 June 2002. The companies signed a "secrecy agreement" before the meeting, it is alleged. Acambis requested a licensing proposal, but backtracked, it is claimed.
    The two sides were negotiating a deal whereby Acambis would license intellectual property surrounding MVA. But Acambis signed a deal with the US government's National Institutes of Health (NIH), which had been working on MVA. Bavarian says the NIH was using its secrets, which were not the US government's to sign away.

    It tried unsuccessfully to prevent the NIH from releasing its MVA strain to Acambis, the court documents reveal. "The virus was originally provided to Dr Moss [Bernard Moss of the NIH] for research and not for commercialisation into vaccine products," it claims.

    The NIH was keen to generate a competitive tender for the contract to supply up to 80 million doses of MVA, which could be worth $1bn. It faced domestic criticism for awarding a contract for a stockpile of anthrax drugs to a single supplier, and it is expected that the MVA contract will be shared between Acambis and Bavarian Nordic.

    Acambis refused to comment yesterday on the specifics revealed in the court documents.

    news.independent.co.uk/business/news/...
  15. forum rang 4 Pitmans 15 oktober 2022 11:09

    • Pitmans

      Lid sinds: 18 feb 2003

      Laatste bezoek: 28 mrt 2025

    • Aanbevelingen

      Ontvangen: 1114

      Gegeven: 152

    •    Aantal posts: 8.029

    $361 op 19 aug, $214 nu. Dat is niet bepaald stijgen.
    Maar ja, het marktsentiment zit gewoon wat tegen.
15 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.119
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.157
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.857
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.837
Aedifica 3 926
Aegon 3.258 323.073
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.905
Agfa-Gevaert 14 2.062
Ahold 3.538 74.353
Air France - KLM 1.025 35.290
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.050
Alfen 16 25.268
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 420
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.861
AMG 971 134.341
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.056
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.806
Arcelor Mittal 2.034 320.970
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.351
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.607
ASML 1.766 110.070
ASR Nederland 21 4.512
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.926
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449

Macro & Bedrijfsagenda

  1. 28 maart

    1. Producentenprijzen februari (NL)
    2. Producentenvertrouwen maart (NL)
    3. InPost Q4-cijfers
    4. Consumentenvertrouwen april (Dld)
    5. Economische groei Q4 def. (VK)
    6. Detailhandelsverkopen februari (VK)
    7. Inflatie maart vlpg (Fra)
    8. Inflatie maart (Spa)
    9. Werkloosheid maart (Dld)
    10. Consumentenvertrouwen en economisch sentiment maart def. (eur)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda